Cancer Science · 2014 · 23 citations · 27 references
MedicineOncologyPharmacologyDrug DiscoveryMetastasisMolecular OncologyTargeted Cancer TherapyTargeted TherapyTyrosine Kinase InhibitorsEgfr InhibitionEpidermal Growth Factor Receptor InhibitionEpidermal Growth Factor Receptor SignalingHer2 ExpressionHer2 InhibitorsHer2 Receptor TargetingHuman Epidermal Growth Factor Receptor 2-Targeted TherapyReversible Tyrosine Kinase Inhibitors
Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) are validated molecular targets in cancer therapy. Dual blockade has been explored and one such agent, lapatinib, is in clinical practice but with modest activity. Through chemical screening, we discovered a novel EGFR and HER2 inhibitor, S-222611, that selectively inhibited both kinases with IC50 s below 10 nmol/L. S-222611 also inhibited intracellular kinase activity and the growth of EGFR-expressing and HER2-expressing cancer cells. In addition, S-222611 showed potent antitumor activity over lapatinib in a variety of xenograft models. In evaluations with two patient-oriented models, the intrafemoral implantation model and the intracranial implantation model, S-222611 exhibited excellent activity and could be effective against bone and brain metastasis. Compared to neratinib and afatinib, irreversible EGFR/HER2 inhibitors, S-222611 showed equivalent or slightly weaker antitumor activity but a safer profile. These results indicated that S-222611 is a potent EGFR and HER2 inhibitor with substantially better antitumor activity than lapatinib at clinically relevant doses. Considering the safer profile than for irreversible inhibitors, S-222611 could be an important option in future cancer therapy.
27
Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014 · 2K citations
Medicine, Oncology, Pharmacology +11
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Edgar R. Wood, Anne T. Truesdale, Octerloney B. McDonald et al. · Cancer Research · 2004 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +14
Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology · 2012 · 742 citations
Medicine, Oncology, Pharmacology +16